Research statistics
Sermorelin research: publications and trials
At a glance
Publications, all years
373
Since 1984
Publications in 2026 so far
4
Through November 15, 2026
Human clinical research
23.7%
87 of 367 classified
Registered clinical trials
0
ClinicalTrials.gov
Randomized controlled trials
19
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
71.7%
191 animal · 70 in vitro · 2 computational
Records that only mention it
75
Not counted above
Status in the library: Research only. Groups: Growth hormone axis. 6 publications are not yet classified by study type.
What to keep in mind
- More than 70% of the indexed publications are animal, cell or computational studies.
Publications by year
Sermorelin publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1984 | 3 | 5 | 0 | 0 | 8 |
| 1985 | 3 | 10 | 0 | 0 | 13 |
| 1986 | 12 | 5 | 1 | 0 | 18 |
| 1987 | 7 | 12 | 0 | 2 | 21 |
| 1988 | 6 | 13 | 0 | 3 | 22 |
| 1989 | 8 | 7 | 0 | 0 | 15 |
| 1990 | 9 | 12 | 0 | 0 | 21 |
| 1991 | 1 | 20 | 0 | 0 | 21 |
| 1992 | 1 | 15 | 0 | 1 | 17 |
| 1993 | 7 | 5 | 0 | 0 | 12 |
| 1994 | 3 | 4 | 1 | 0 | 8 |
| 1995 | 4 | 7 | 0 | 0 | 11 |
| 1996 | 7 | 7 | 0 | 0 | 14 |
| 1997 | 5 | 7 | 1 | 1 | 14 |
| 1998 | 3 | 5 | 0 | 0 | 8 |
| 1999 | 2 | 5 | 1 | 1 | 9 |
| 2000 | 1 | 8 | 0 | 0 | 9 |
| 2001 | 0 | 3 | 0 | 0 | 3 |
| 2002 | 0 | 1 | 0 | 0 | 1 |
| 2003 | 0 | 6 | 1 | 0 | 7 |
| 2004 | 1 | 4 | 0 | 0 | 5 |
| 2005 | 1 | 6 | 0 | 0 | 7 |
| 2006 | 1 | 1 | 0 | 1 | 3 |
| 2007 | 0 | 3 | 0 | 0 | 3 |
| 2008 | 0 | 7 | 0 | 0 | 7 |
| 2009 | 0 | 3 | 0 | 0 | 3 |
| 2010 | 0 | 7 | 0 | 0 | 7 |
| 2011 | 0 | 9 | 0 | 1 | 10 |
| 2012 | 0 | 12 | 1 | 0 | 13 |
| 2013 | 0 | 2 | 0 | 0 | 2 |
| 2014 | 0 | 3 | 0 | 0 | 3 |
| 2015 | 0 | 4 | 0 | 0 | 4 |
| 2016 | 1 | 5 | 0 | 0 | 6 |
| 2017 | 1 | 3 | 0 | 1 | 5 |
| 2018 | 0 | 5 | 0 | 0 | 5 |
| 2019 | 0 | 2 | 0 | 0 | 2 |
| 2020 | 0 | 5 | 1 | 1 | 7 |
| 2021 | 0 | 8 | 0 | 0 | 8 |
| 2022 | 0 | 4 | 0 | 0 | 4 |
| 2023 | 0 | 6 | 0 | 0 | 6 |
| 2024 | 0 | 3 | 1 | 0 | 4 |
| 2025 | 0 | 2 | 0 | 1 | 3 |
| 2026 (to date) | 0 | 2 | 2 | 0 | 4 |
Study types
| Animal study | 191 |
|---|---|
| In vitro study | 70 |
| Other clinical trial | 58 |
| Randomized controlled trial | 19 |
| Review | 10 |
| Observational human study | 9 |
| Editorial, letter or other | 7 |
| Not yet classified | 6 |
| Computational study | 2 |
| Case report | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Endocrinology | 169 |
|---|---|
| Neurological and mental health | 85 |
| Oncology | 84 |
| Reproductive and sexual health | 49 |
| Metabolic health | 33 |
| Longevity and aging | 18 |
| Obesity and weight management | 18 |
| Immune system | 16 |
| Cardiovascular | 15 |
| Gastrointestinal | 12 |
| Dermatology | 11 |
| Musculoskeletal | 8 |
Registered clinical trials
A registration is not a result.
No registered trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.
European journal of endocrinology · August 1, 2005 · Randomized controlled trial · cited 11 times
PMID 16061831 · DOI 10.1530/eje.1.01965 · Human clinical research
- Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep.
European journal of endocrinology · November 1, 2004 · Randomized controlled trial · cited 16 times
PMID 15538933 · DOI 10.1530/eje.0.1510561 · Human clinical research
- The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.
European journal of endocrinology · April 1, 2000 · Randomized controlled trial · cited 20 times
PMID 10754477 · DOI 10.1530/eje.0.1420359 · Human clinical research
- Quantitative growth hormone secretion and final adult height.
Clinical endocrinology · November 1, 1999 · Randomized controlled trial · cited 1 times
PMID 10594520 · DOI 10.1046/j.1365-2265.1999.00844.x · Human clinical research
- The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.
Clinical endocrinology · November 1, 1999 · Randomized controlled trial · cited 10 times
PMID 10594518 · DOI 10.1046/j.1365-2265.1999.00839.x · Human clinical research
- Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.
The Journal of clinical endocrinology and metabolism · April 1, 1998 · Randomized controlled trial · cited 97 times
PMID 9543138 · DOI 10.1210/jcem.83.4.4711 · Human clinical research
- Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.
The Journal of clinical endocrinology and metabolism · November 1, 1997 · Randomized controlled trial · cited 37 times · open access
PMID 9360512 · DOI 10.1210/jcem.82.11.4363 · Human clinical research
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
The Journal of clinical endocrinology and metabolism · May 1, 1997 · Randomized controlled trial · cited 54 times
PMID 9141536 · DOI 10.1210/jcem.82.5.3943 · Human clinical research
- Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature.
Metabolism: clinical and experimental · September 1, 1995 · Randomized controlled trial · cited 21 times
PMID 7666796 · DOI 10.1016/0026-0495(95)90016-0 · Human clinical research
- GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.
Clinical endocrinology · September 1, 1995 · Randomized controlled trial · cited 22 times
PMID 7586605 · DOI 10.1111/j.1365-2265.1995.tb02042.x · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.
Endocrinology · June 1, 1989 · Animal study · cited 297 times
PMID 2541999 · DOI 10.1210/endo-124-6-2791 · Animal studies
- Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.
Endocrinology · February 1, 1992 · Animal study · cited 232 times
PMID 1346381 · DOI 10.1210/endo.130.2.1346381 · Animal studies
- Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
Endocrinology · June 1, 1985 · Animal study · cited 154 times
PMID 2859987 · DOI 10.1210/endo-116-6-2643 · Animal studies
- GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
Clinical endocrinology · December 1, 1987 · Other clinical trial · cited 118 times
PMID 2901302 · DOI 10.1111/j.1365-2265.1987.tb02957.x · Human clinical research
- Super-active analogs of growth hormone-releasing factor (1-29)-amide.
Biochemical and biophysical research communications · February 1, 1984 · Animal study · cited 115 times
PMID 6231028 · DOI 10.1016/0006-291x(84)91647-4 · Animal studies
Latest publications
- Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of growth hormone-releasing hormone.
American journal of physiology. Heart and circulatory physiology · August 1, 2026 · Animal study · cited 0 times · open access
PMID 42541513 · DOI 10.1152/ajpheart.00118.2026 · Animal studies
- Growth hormone - releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation.
Experimental eye research · July 15, 2026 · In vitro study · cited 1 times
PMID 42456877 · DOI 10.1016/j.exer.2026.111168 · In vitro studies
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · June 18, 2026 · Review · cited 1 times · open access
PMID 42395176 · DOI 10.3389/fendo.2026.1822475 · Reviews and meta-analyses
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · April 12, 2026 · Review · cited 8 times · open access
PMID 41966639 · DOI 10.1007/s40279-026-02437-0 · Reviews and meta-analyses
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Journal of pharmaceutical and biomedical analysis · October 20, 2025 · Editorial, letter or other · cited 1 times
PMID 41138283 · DOI 10.1016/j.jpba.2025.117207 · Commentary and other
- Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · October 9, 2025 · In vitro study · cited 1 times
PMID 41075421 · DOI 10.1016/j.ghir.2025.101668 · In vitro studies
- Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
International journal of molecular sciences · April 1, 2025 · In vitro study · cited 1 times · open access
PMID 40244089 · DOI 10.3390/ijms26073267 · In vitro studies
- Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.
International journal of molecular sciences · October 18, 2024 · Animal study · cited 2 times · open access
PMID 39456984 · DOI 10.3390/ijms252011200 · Animal studies
- A novel approach for the treatment of AML, through GHRH antagonism: MIA-602.
Reviews in endocrine & metabolic disorders · October 17, 2024 · Review · cited 3 times · open access
PMID 39417961 · DOI 10.1007/s11154-024-09917-6 · Reviews and meta-analyses
- Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Oncotarget · April 8, 2024 · Animal study · cited 7 times · open access
PMID 38588464 · DOI 10.18632/oncotarget.28579 · Animal studies
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: GRF 1-29; Groliberin; Semorelin; Sermorelin; Sermorelina; Sermoreline; Sermorelinum; Sermorlin
((TITLE_ABS:"GRF 1-29" OR CHEM:"GRF 1-29" OR TITLE_ABS:"GRF1-29" OR CHEM:"GRF1-29") OR (TITLE_ABS:"Groliberin" OR CHEM:"Groliberin") OR (TITLE_ABS:"Semorelin" OR CHEM:"Semorelin") OR (TITLE_ABS:"Sermorelin" OR CHEM:"Sermorelin") OR (TITLE_ABS:"Sermorelina" OR CHEM:"Sermorelina") OR (TITLE_ABS:"Sermoreline" OR CHEM:"Sermoreline") OR (TITLE_ABS:"Sermorelinum" OR CHEM:"Sermorelinum") OR (TITLE_ABS:"Sermorlin" OR CHEM:"Sermorlin")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Sermorelin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/sermorelin